NASDAQ : RZLT
Rezolute, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.95 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 414.34M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 414.34M |
| Enterprise Value | 307.48M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 96.72M |
| Shares Outstanding | 104.90M |
| Shares Change (YoY) | +36.72% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 73.14% |
| Float | 65.91M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 161.85 |
| PB Ratio | 3.78 |
| P/TBV Ratio | 4.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.68 |
| Quick Ratio | 9.44 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -59.04% |
| Return on Assets (ROA) | -35.32% |
| Return on Invested Capital (ROIC) | -38.37% |
| Return on Capital Employed (ROCE) | -80.32% |
| Weighted Average Cost of Capital (WACC) | 7.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.34M |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -58.55% |
| 50-Day Moving Average | 4.25 |
| 200-Day Moving Average | 3.89 |
| Relative Strength Index (RSI) | 45.86 |
| Average Volume (20 Days) | 1,613,601 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19.17M |
| Short Previous Month | 16.71M |
| Short % of Shares Out | 18.27% |
| Short % of Float | 29.08% |
| Short Ratio (days to cover) | 10.32 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -81.47M |
| Pretax Income | -77.59M |
| Net Income | -77.59M |
| EBITDA | -81.44M |
| EBIT | -81.47M |
| Earnings Per Share (EPS) | -$0.75 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 107.80M |
| Total Debt | 934,000 |
| Net Cash | 106.87M |
| Net Cash Per Share | $1.02 |
| Equity (Book Value) | 100.69M |
| Book Value Per Share | 1.04 |
| Working Capital | 99.09M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -64.64M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 31,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -64.64M |
| FCF Per Share | -$0.62 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.72% |
| Shareholder Yield | -36.72% |
| Earnings Yield | -18.90% |
| FCF Yield | -15.60% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.80 |
| Price Target Difference | 148.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 13, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |